Emmanuelle M Clerisme-Beaty MD
Critical Care Medicine, Pleural Disease
Physician
Join to View Full Profile
12 Night Hawk LnSandy Hook, CT 06482
Phone+1 203-417-0714
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Emmanuelle Clerisme-Beaty, MD is a pulmonologist in Sandy Hook, Connecticut. She is currently licensed to practice medicine in Connecticut and Maryland.
Education & Training
Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine, 2002 - 2005
Yale School of MedicineClass of 2002
Certifications & Licensure
CT State Medical License 2004 - 2025- CT State Medical License 2004 - 2025
MD State Medical License 2007 - 2012
Publications & Presentations
PubMed
- 14 citationsStudy design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.Robin R. Deterding, Matthias Griese, Gail H. Deutsch, David Warburton, Emily M. DeBoer
ERJ Open Research. 2021-04-01 - 108 citationsEfficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSC...Kristin B. Highland, Oliver Distler, Masataka Kuwana, Yannick Allanore, Shervin Assassi
The Lancet. Respiratory Medicine. 2021-01-01 - 151 citationsThe natural history of progressive fibrosing interstitial lung diseases.Kevin K. Brown, Fernando J. Martinez, Simon L.F. Walsh, Victor J. Thannickal, Antje Prasse
The European Respiratory Journal. 2020-01-01
Press Mentions
Newly Published Trial Results Showed Spesolimab Significantly Improved Signs and Symptoms of Flare in Rare, Life-Threatening Skin Disease, Generalized Pustular PsoriasisDecember 23rd, 2021- Newly Published Trial Results Showed Spesolimab Significantly Improved Signs and Symptoms of Flare in Rare, Life-Threatening Skin Disease, Generalized Pustular PsoriasisDecember 22nd, 2021
